Episode 2: Kevin Outterson, CARB-X director; a new anti-gonorrhoeal drug; AMR burden in Europe.


In this episode we feature an interview with the director of the CARB-X program, Professor Kevin Outterson, and inaugurating our news section, we bring to you an exciting new drug to treat gonorrhoeal infections and the most recent estimations of AMR burden in Europe.

You can follow us and subscribe to our podcast to get new episodes directly in your preferred device and platform:

iTunesSpotify & SoundCloud

or you can listen to this second episode right here:

Relevant links:

  • CARB-Xnon-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
  • SIDR: Social Innovation on Drug Resistance Postdoctoral Program.
  • Drive ABdeveloping new economic models to incentivise antibiotic discovery and development activities while safeguarding the efficacy of antibiotics by researching and advocating their appropriate use.
  • ReAct: one of the first international independent networks to articulate the complex nature of antibiotic resistance and its drivers.
  • Drugs for Neglected Diseases initiative (DNDi): collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases.
  • Global Antibiotic Research & Development Partnership (GARDP)joint initiative of DNDi and the WHO, aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists.

Further Reading:

If you have any comments and suggestions you can email us here, or tweet to us (@UAC_UU) using the hashtag #theAMRStudio.